ANDA 87511, held by Lederle. Hydrochlorothiazide; Spironolactone.
As of Nov 16, 2026, ANDA 87511 (Spironolactone W/ Hydrochlorothiazide), held by Lederle, was not approved, with 4 approved supplements and 0 published complete response letters.
| Product | Active ingredient | Marketing |
|---|---|---|
| Spironolactone W/ Hydrochlorothiazide25MG;25MG ยท tablet;oral | Hydrochlorothiazide; Spironolactone | Discontinued |
| Feb 25, 1985 | Supplement 5Manufacturing | Approved | None posted |
| Mar 30, 1983 | Supplement 2Manufacturing | Approved | None posted |
| Mar 30, 1983 | Supplement 3Manufacturing | Approved | None posted |
| Mar 30, 1983 | Supplement 4Manufacturing | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters